Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study-Reference-Cited by-同舟云学术

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study

Published:2024-04 Issue:4 Volume:25 Page:518-528
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kim Stefano,Ghiringhelli Francois,de la Fouchardière Christelle,Evesque Ludovic,Smith Denis,Badet Nicolas,Samalin Emmanuelle,Lopez-Trabada Ataz Daniel,Parzy Aurelie,Desramé Jérôme,Baba Hamed Nabil,Buecher Bruno,Tougeron David,Bouché Olivier,Dahan Laetitia,Chibaudel Benoist,El Hajbi Farid,Mineur Laurent,Dubreuil Olivier,Ben Abdelghani Meher,Pecout Solange,Bibeau Frederic,Herfs Michael,Garcia Marie-Line,Meurisse Aurelia,Vernerey Dewi,Taïeb Julien,Borg Christophe

Funder

Roche

Publisher

Elsevier BV

Reference29 articles.

1. Anal Cancer: emerging standards in a rare disease;Eng;J Clin Oncol,2022

2. International trends in anal cancer incidence rates;Islami;Int J Epidemiol,2017

3. Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: an ancillary study to the Epitopes-HPV02 trial;Debernardi;Front Oncol,2022

4. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study;Kim;Lancet Oncol,2018

5. Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the Epitopes-HPV02 trial;Bernard-Tessier;Clin Cancer Res,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09

2. Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance;Current Oncology Reports;2024-06-11

3. Combining chemotherapy and immunotherapy for advanced anal cancer: are we ready?;The Lancet Oncology;2024-04